Multiple Myeloma Market Report 2026

Multiple Myeloma Market Overview

• Multiple Myeloma market size has reached to $28.05 billion in 2025 • Expected to grow to $41.39 billion in 2030 at a compound annual growth rate (CAGR) of 8.2% • Growth Driver: Increasing Prevalence Of Multiple Myeloma Drives Multiple Myeloma Drives Market • Market Trend: Novel Therapy To Gain A Competitive Edge In The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Multiple Myeloma Market?

Multiple myeloma is a cancer that appears in a type of white blood cell called a plasma cell. Cancerous plasma cells build up in the bone marrow and crowd out healthy blood cells in multiple myeloma. Cancer cells produce abnormal proteins that may cause problems rather than helpful antibodies. The main treatments for multiple myeloma include medications, radiation therapy, stem cell transplant, and others. Medication refers to a dosage form that contains both potential inert substances and one or more active chemicals. Blood tests, bone marrow biopsy, urine tests, and imaging tests are used for active multiple myeloma and smoldering multiple myeloma diseases and the treatment can be distributed by the hospital pharmacy, retail pharmacy, online pharmacy, and other channels.

What Is The Multiple Myeloma Market Growth Forecast?

The multiple myeloma market size is expected to see strong growth in the next few years. It will grow to $41.39 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to advancements in targeted therapies, rising demand for stem cell transplants, growth in precision medicine applications, increasing clinical trials pipeline, expanding use of monoclonal antibody therapies. Major trends in the forecast period include increasing development of novel immunotherapies, growing use of monoclonal antibodies in treatment regimens, rising adoption of minimally invasive diagnostic techniques, expansion of stem cell transplantation procedures, increased focus on combination therapies for improved outcomes.

Global Multiple Myeloma Market Segmentation

1) By Treatment: Medications, Radiation Therapy, Stem Cell Transplant, Other Treatments 2) By Diagnosis: Blood Tests, Bone Marrow Biopsy, Urine Tests, Imaging Tests 3) By Disease Type: Active Multiple Myeloma, Smoldering Multiple Myeloma 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels Subsegments: 1) By Medications: Immunomodulatory Drugs (IMiDs), Proteasome Inhibitors, Monoclonal Antibodies, Corticosteroids, Chemotherapy Agents 2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Radioisotope Therapy 3) By Stem Cell Transplant: Autologous Stem Cell Transplant (ASCT), Allogeneic Stem Cell Transplant 4) By Other Treatments: Supportive Care, Clinical Trials And Experimental Therapies

What Is The Driver Of The Multiple Myeloma Market?

The increasing prevalence of multiple myeloma is expected to propel the growth of the multiple myeloma market going forward. Multiple myeloma is a cancer that appears in a type of white blood cell called a plasma cell. The increase in multiple myeloma is due to age, genetics, obesity, radiation exposure, and other conditions. Multiple myeloma treatment slows its spread and makes symptoms go away. For instance, in February 2025, according to the American Cancer Society, a US-based voluntary health organization, projections for the United States indicate that around 36,110 new multiple myeloma cases and approximately 12,030 related deaths are expected in 2025, affecting both men and women. Therefore, the increasing prevalence of multiple myeloma is driving the growth of the multiple myeloma industry

Key Players In The Global Multiple Myeloma Market

Major companies operating in the multiple myeloma market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Janssen Global Services LLC, Celgene Corporation, Biogen Inc., Cipla Inc., Sun Pharmaceutical Industries Ltd., Karyopharm Therapeutics Inc., Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., Xencor Inc., Oncopeptides AB, BeiGene Ltd., TG Therapeutics Inc.

Global Multiple Myeloma Market Trends and Insights

Major companies in the multiple myeloma market are focused on developing novel therapies, such as CAR T-cell therapy, to gain a competitive edge in the market. CAR T-cell therapy (Chimeric Antigen Receptor T-cell therapy) is an immunotherapy that involves genetically modifying a patient's T cells to express a chimeric antigen receptor, enabling them to recognize and target specific cancer cells. For instance, in December 2023, Bristol Myers Squibb, a US-based biopharmaceutical company, received approval for Abecma, as the first CAR T-cell therapy for earlier use in patients with relapsed or refractory multiple myeloma (RRMM) who have undergone at least two prior therapies. Abecma is a B-cell maturation antigen (BCMA)-directed CAR T-cell immunotherapy. The approval is based on the interim analysis of the KarMMa-3 Phase 3 study, demonstrating a significant increase in median progression-free survival (mPFS) and a higher overall response rate (ORR) in the Abecma arm.

What Are Latest Mergers And Acquisitions In The Multiple Myeloma Market?

In February 2024, AstraZeneca Plc, a UK-based pharmaceutical company acquired Gracell Biotechnologies Inc. for an undisclosed amount. This acquisition signals AstraZeneca's strategic move to strengthen its position in the field of immuno-oncology and cellular therapies, leveraging Gracell's innovative platform and expertise. Gracell Biotechnologies Inc. is a China-based company that focuses on clinical development of FasTCAR-T GC012F in multiple myeloma.

Regional Outlook

North America was the largest region in the multiple myeloma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Multiple Myeloma Market?

The multiple myeloma market consists of revenues earned by entities by providing services such as treatment planning, supportive care, and diagnostic testing such as computerized tomography (CT scans), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans. The market value includes the value of related goods sold by the service provider or included within the service offering. The multiple myeloma market also includes sales of thalidomide, bortezomib, and daratumumab which are used in providing multiple myeloma services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Multiple Myeloma Market Report 2026?

The multiple myeloma market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the multiple myeloma industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.